Evidence map›Paper›PMID 39651842›Full record

ArticleACS infectious diseases2025

Mode of Action and Mechanisms of Resistance to the Unusual Polyglycosylated Thiopeptide Antibiotic Persiathiacin A.

Jason Woodgate, Felaine A Sumang, Mary E Salliss, Matthew Belousoff, Alan C Ward, Gregory L Challis, Nikolay Zenkin, Jeff Errington, Yousef Dashti

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jason WoodgateCentre for Bacterial Cell Biology, Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne NE2 4AX, U.K.ORCID 0000-0002-8314-7192
Felaine A SumangFaculty of Medicine and Health, University of Sydney, Sydney, NSW 2015, Australia.ORCID 0009-0009-1050-6236
Mary E SallissFaculty of Medicine and Health, University of Sydney, Sydney, NSW 2015, Australia.ORCID 0009-0009-9627-5095
Matthew BelousoffCentre for Cryo Electron Microscopy of Membrane Proteins, Monash Institute of Pharmaceutical Sciences, Parkville, VIC 3052, Australia.ORCID 0000-0002-3229-474X
Alan C WardSchool of Biology, Newcastle University, Newcastle upon Tyne NE2 4AX, U.K.
Gregory L ChallisDepartment of Chemistry, University of Warwick, Coventry CV4 7AL, U.K.ORCID 0000-0001-5976-3545
Nikolay ZenkinCentre for Bacterial Cell Biology, Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne NE2 4AX, U.K.ORCID 0000-0003-2212-9545
Jeff ErringtonFaculty of Medicine and Health, University of Sydney, Sydney, NSW 2015, Australia.ORCID 0000-0002-6977-9388
Yousef DashtiFaculty of Medicine and Health, University of Sydney, Sydney, NSW 2015, Australia.ORCID 0000-0002-8490-7763

Funding

Wellcome TrustWellcome Trust 209500
6 · The paper itself

Abstract

Persiathiacin A is a novel thiopeptide antibiotic produced by

Indexed as

Anti-Bacterial AgentsDrug Resistance, BacterialBacillus subtilisBacterial ProteinsMethicillin-Resistant Staphylococcus aureusMicrobial Sensitivity TestsMutationProtein BiosynthesisRibosomal ProteinsRibosomesAnti-Bacterial AgentsBacterial ProteinsRibosomal ProteinsRibosomal protein L11RiPPSelf-resistanceTranslation inhibition

Identifiers

PMID39651842
PMCPMC11731312

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.